Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-1701 + capecitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
SHR-1701 is a bifunctional fusion protein composed of a monoclonal antibody against PD-L1 fused with the extracellular domain of TGF-β receptor II. It simultaneously blocks PD-L1 and TGF-β signaling pathways, aiming to enhance anti-tumor immune responses by overcoming immune suppression in the tumor microenvironment. Capecitabine is an oral prodrug that is converted to 5-fluorouracil (5-FU) in the body and acts as an antimetabolite chemotherapeutic agent inhibiting DNA synthesis. Oxaliplatin is a platinum-based chemotherapeutic that causes DNA crosslinking and apoptosis in cancer cells. The combination of SHR-1701 with capecitabine and oxaliplatin (CAPOX) has been investigated for use in unresectable, locally advanced or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma, showing superior overall survival compared to chemotherapy alone[4][5].
- Other names
- CAPOX
02
Targets
TGFB (GARP–latent transforming growth factor beta 1 complex)CD274 (Programmed cell death protein 1 ligand 1)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on SHR-1701 + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-1701 + capecitabine + oxaliplatin.